Sort
8,912 grants matching “sars cov 2”
Systems biological assessment of B cell responses to vaccination
$309,746Scott Dexter Boyd · Stanford University · U19 · FY2022 · AI
Human Immune Monitoring Core
$309,746Holden T. Maecker · Stanford University · U19 · FY2022 · AI
Systems Immunogenetics of Biodefense and Emerging Pathogens in the Collaborative Cross
$309,479Ralph S Baric · Univ Of North Carolina Chapel Hill · U19 · FY2021 · AI
Acute Inhibition of TAK1 as a Means to Control COVID-19 Pulmonary Hyperinflammation
$309,288Scott Scarneo · Eydis Bio, Inc. · R43 · FY2021 · HL
De Novo Designed Protein Nanoparticle Agonists Targeting the Tie2 Receptor for the Treatment of ARDS and Sepsis in Patients with COVID-19
$308,875George Ueda · University Of Washington · R21 · FY2021 · AI
A Nomogram to Predict Seizure Outcomes after Resective Epilepsy Surgery
$308,248Lara Jehi · Cleveland Clinic Lerner Com-Cwru · R01 · FY2020 · NS
In vitro modeling to characterize mechanisms of neonatal vaccine induced immune responses
$308,143Ofer Levy · Boston Children'S Hospital · U19 · FY2020 · AI
IMmunoPhenotyping Assessment of a Covid-19 Cohort (IMPACC): Immunophenotyping of innate and adaptive immune response to SARS-CoV-2 infection.
$308,143Ofer Levy · Boston Children'S Hospital · U19 · FY2020 · AI
Flu Dynamics COVID-19 Supplement
$308,116Aubree L Gordon · University Of Michigan At Ann Arbor · R01 · FY2021 · AI
Vaccine and Treatment Evaluation Units (VTEU)-DMID 21-0004
$308,091Hana M El Sahli · Baylor College Of Medicine · UM1 · FY2021 · AI
CEIRS: SARS-CoV-2 RESEARCH
$308,000Adolfo Garcia-Sastre · Icahn School Of Medicine At Mount Sinai · N01 · FY2021 · AI
COVID-19 Neurological Georgia Cohort Study
$308,000David C Hess · Augusta University · R01 · FY2020 · NS
Structural Genomics Centers for Infectious Diseases: SARS-CoV-2 Research Activities
$307,531Karla Satchell · Northwestern University At Chicago · N01 · FY2021 · AI
Influenza & COVID Obstetric and Perinatal Epidemiology Study in India
$307,288Patricia L Hibberd · Boston University Medical Campus · R01 · FY2025 · HD
Development of therapeutics for SARS-CoV-2 infection
$307,226Hiroaki Mitsuya · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Targeting polyamines to suppress SARS-CoV-2 related disease
$306,997Natalia A Ignatenko · University Of Arizona · UG3 · FY2022 · TR
Targeting polyamines to suppress SARS-CoV-2 related disease
$306,997Natalia A Ignatenko · University Of Arizona · UG3 · FY2021 · TR
Core-- Animal Models
$306,973Mark T Heise · Univ Of North Carolina Chapel Hill · P01 · FY2008 · AI
Three-Dimensional Spatio-Temporal Control of Lipid Nanoparticle Manufacturing for Improved Nucleic Acid Delivery
$306,873Po-Lun Feng · Osem Fluidics Inc · R43 · FY2025 · GM
Core E Data Management Core
$306,843Harm Van Bakel · Icahn School Of Medicine At Mount Sinai · U19 · FY2023 · AI
Core E Data Management Core
$306,839Harm Van Bakel · Icahn School Of Medicine At Mount Sinai · U19 · FY2024 · AI
EAGER: Quantifying SARS-CoV-2 antigen-antibody binding using cell-free guide RNA display
$306,500James Carothers · University Of Washington · · FY2020 · BIO
Development of Host- Oriented Therapeutics Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),
$306,500Ronald N. Harty · Fox Chase Chemical Diversity Center, Inc · R41 · FY2022 · AI
Determinants of Coronavirus Fidelity in Replication and Pathogenesis
$306,487Mark R Denison · Vanderbilt University Medical Center · R01 · FY2015 · AI
Development of a Neutrophil Degranulation Inhibitor to Treat ARDS
$306,424Kenneth R McLeish · Degranin Therapeutics, Llc · R43 · FY2023 · HL